Status:

COMPLETED

COVID-19 Brain Injury

Lead Sponsor:

University of Pittsburgh

Conditions:

Sars-CoV2

Severe Neurologic Injury

Eligibility:

All Genders

18+ years

Brief Summary

A prospective cohort minimal risk study to determine the impact of the COVID-19 crisis on outcomes of neurologically injured ICU patients.

Detailed Description

COVID 19 pandemic has overwhelmed healthcare capacity in many regions around the world. As resources become more limited and we have to triage /ration ventilators, neurologically injured ICU patients ...

Eligibility Criteria

Inclusion

  • Patients greater than or equal to 18
  • Patients who require critical care with primary diagnoses of: Acute ischemic stroke (AIS), acute intracerebral hemorrhage (ICH), acute subarachnoid hemorrhage (SAH), acute traumatic brain injury (TBI), status epilepticus (SE) patients requiring critical care

Exclusion

  • Patients under the age of 18 years old
  • Pre-existing Do Not Resuscitate (DNR), Do Not Intubate (DNI), or Comfort Measures Only (CMO) status prior to acute hospitalization
  • Neurologically morbid-bound on hospital arrival (bilateral fix/dilated pupils, catastrophic bleed/TBI) and likely to progress to brain death within 48 hrs

Key Trial Info

Start Date :

April 2 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

May 31 2021

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT04496076

Start Date

April 2 2020

End Date

May 31 2021

Last Update

August 16 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15261